Cerus (CERS) vs InfuSystems (INFU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InfuSystems (INFU) has outperformed Cerus (CERS) over the past year, gaining 51.7% versus a gain of 14.2%. Over five years, INFU leads with a -15.9% price change compared with -73.5% for CERS. Cerus is the larger company by market cap ($373.6 million vs $287.5 million), about 1.3 times the size.
On valuation, InfuSystems trades at a lower forward P/E (25.6x vs 123.3x for Cerus). InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -6.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERS | INFU |
|---|---|---|
| Share price | $1.85 | $14.35 |
| Market cap | $373.62M | $287.48M |
| 1-day change | -2.63% | +2.06% |
| YTD return | -10.19% | +59.98% |
| 1-year return | +14.20% | +51.69% |
| 5-year return | -73.50% | -15.93% |
| P/E ratio (TTM) | — | 32.61 |
| Forward P/E | 123.33 | 25.63 |
| EPS (TTM) | $-0.04 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $233.80M | $143.44M |
| Revenue growth (YoY) | +16.13% | +6.36% |
| Net income (latest FY) | $-15.63M | $6.63M |
| Gross margin | — | 55.98% |
| Operating margin | -3.71% | 8.31% |
| Net margin | -6.68% | 4.62% |
| 52-week high | $3.47 | $15.47 |
| 52-week low | $1.59 | $7.29 |
| Distance from 52-week high | -46.69% | -7.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +177.30% | +28.92% |
| Average volume | 2.12M | 136.60K |
| Shares outstanding | 201.95M | 20.03M |
| Employees | 261 | 461 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed CERS by 37.5 percentage points over the past year.
- InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
- Cerus grew revenue faster in its latest fiscal year (+16.13% vs +6.36%).
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Health Care · Medical/Dental Instruments · 261 employees
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
CERS vs INFU FAQ
Which is bigger, Cerus or InfuSystems?
Cerus (CERS) is larger, with a market capitalization of $373.62M compared with $287.48M for InfuSystems (INFU).
Which stock has performed better over the past year, CERS or INFU?
INFU returned +51.69% over the past 12 months, compared with +14.20% for CERS (price return, excluding dividends). Past performance does not predict future results.
Are Cerus and InfuSystems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.